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1. Introduction 
Cocaine addiction continues to be an important public health problem in the United States 
and other countries. Acute cocaine produces potent rewarding and psychostimulant 
effects primarily by blocking dopamine (DA) transporters (DAT) in the brain's reward 
system – the mesocorticolimbic DA system. However, repeated use of cocaine leads to 
addiction, persistent craving and a high risk of relapse. To date, there are no proven 
pharmacotherapies for cocaine addiction. Recent progress in the neurobiology of drug 
dependence in preclinical animal models has lead to the discovery of various novel 
compounds that appear to be promising for the treatment of drug addiction. Some have 
been tested in controlled clinical trials and have produced encouraging results in reducing 
cocaine use and in increasing abstinence from relapse. In this review article, I will focus 
on those medication strategies that are well-studied in experimental animals and are 
currently under clinical trials for the treatment of addiction or for other diseases. These 
strategies include DAT-based agonist therapy, DA receptor-based antagonist therapy, 
glutamate-based therapy, GABA-based therapy and endocannabinoid-based therapy. For 
each treatment, I will first review the rationale and the underlying neurochemical 
mechanisms of the therapy, and then summarize the major findings of the drugs in each 
category at both preclinical and clinical levels.  
2. Dopamine transporter-based agonist therapies 
Rationale: The mesocorticolimbic DA system is thought to be critically involved in drug 
reward and addiction (Wise, 2005; Sulzer, 2011). This system originates from the DA 
neurons in the ventral tegmental area (VTA) in the midbrain and projects predominantly to 
the nucleus accumbens (NAc) and prefrontal cortex (PFC) in the forebrain (Figure 1). 
Almost all addictive drugs, such as cocaine, heroin, nicotine and alcohol, have been shown 
to increase extracellular DA in the NAc via different mechanisms (Wise, 2005; Sulzer, 2011). 
For example, cocaine elevates extracellular DA by blockade of DAT, while heroin increases 
extracellular DA by inhibition of GABA release in the VTA that disinhibits (activates) DA 
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neurons. Such an increase in NAc DA has been thought to underlie the euphoria associated 
with drug abuse. Based on this DA hypothesis, much attention in medication development 
for treatment of addiction has been focused on manipulation of DA transmission in the 
brain reward circuitry. One strategy is to target DAT (agonist therapy), and another is to 
target brain DA receptors (antagonist therapy) (Figure 2).  
 
Fig. 1. Schematic diagrams, illustrating the mesocorticolimbic DA reward system in human 
(A) and rat (B) brains. The mesocorticolimbic DA system originates in the midbrain ventral 
tegmental area (VTA) and projects predominantly to the nucleus accumbens (NAc) and 
prefrontal cortex (PFC). Dopaminergic afferents from the VTA and glutamatergic afferents 
from the PFC, hippocampus and amygdala synapse on NAc medium-spiny (GABAergic) 
neurons (MSN), which project to the VTA and the ventral pallidum (VP).   
Agonist or substitution therapies have been successful in the treatment of opioid (Mattick et 
al., 2009) and nicotine dependence (Xi et al., 2009; Xi, 2010). As such, drugs that block the 
DAT, but have lower addictive potential than cocaine, would have potential as ‘cocaine-like’ 
agonist therapies for the treatment of cocaine addiction. Indeed, this strategy has been at the 
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forefront of medication development for the treatment of cocaine addiction for more than a 
decade (Rothman and Baumann, 2006; Howell and Kimmel, 2008). To date, many DAT 
inhibitors have been developed, and several of them have been tested in human clinical 
trials (Newman and Kulkarni, 2002; Runyon and Carroll, 2006; Rothman et al., 2006, 2008). 
 
 
Fig. 2. Schematic diagram of the VTA-NAc-VP reward pathway, illustrating the actions of 
acute cocaine on extracellular DA, endocannabinoids (eCBs), glutamate and GABA in the 
NAc and VP, and the sites of action of various mechanism-based pharmacological agents in 
the brain reward system. Cocaine elevates extracellular DA in the NAc by blocking DAT on 
presynaptic DA terminals. DA activates postsynaptic DA receptors, in particular D2 and D3 
receptors, producing an overall inhibitory effect on NAc medium-spiny (GABAergic) 
neurons (MSN). In addition, activation of D2 receptors may also increase eCB release from 
MSNs, which subsequently activates cannabinoid CB1 receptors located on presynaptic 
glutamatergic terminals and GABAergic MSNs themselves, causing a reduction in 
glutamate release and in MSN excitability. Thus, increases in NAc DA and eCBs and a 
reduction in NAc glutamate release lead to a reduction in MSN excitability and GABA 
release in the VTA (not shown) and VP. Decreased GABA release in the VTA causes an 
increase in DA neuron activity (via a disinhibition mechanism) and DA release in the NAc. 
Based upon these neurochemical hypotheses, various pharmacological therapies have been 
proposed and tested in animal models of drug addiction to interfere with cocaine’s action. 
More details are discussed in the text of this review.  
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However, none have proven to be successful due to significant abuse liability by those 
compounds themselves and/or unwanted side-effects. Given the recent finding that 
rewarding and psychostimulant effects of the drugs are positively correlated with the speed 
of onset and offset of action on brain DA (Volkow et al., 1995; Kimmel et al., 2007; Xi and 
Gardner, 2008), it has been proposed that DAT inhibitors (Figure 2), in particular those with 
a slower-onset longer-acting profile than cocaine, would have lower addictive potential by 
themselves. In the following sections, we will review several DAT inhibitors with such a 
slow-onset long-action profile. 
2.1 GBR-12909  
Preclinical studies: GBR-12909 (Vanoxerine), a phenyl-substituted piperazine derivative, is a 
relatively slow-onset long-acting DAT inhibitor compared to cocaine (Howell and Wilcox, 
2001). To date, it is the most extensively studied DAT inhibitor proposed to be beneficial in 
the treatment of cocaine addiction (Rothman et al., 2008). GBR-12909 binds at the DAT site 
with high affinity, and selectively inhibits DA re-uptake. GBR-12909 can also compete with 
psychostimulants at the DAT site, thus blocking cocaine- or amphetamine-induced increases 
in extracellular DA. Compared to the same doses of cocaine, GBR-12909-induced increases 
in striatal DA and locomotion are relatively slow-onset and long-lasting (Baumann et al., 
1991, 1994; Kelley and Lang, 1989). Pretreatment with GBR-12909 significantly inhibits 
cocaine self-administration in rats and nonhuman primates at doses that have little or no 
effect on food self-administration (Glowa et al., 1995). Repeated treatment with low doses of 
GBR-12909 sustains the selective suppression of cocaine self-administration versus food self-
administration (Glowa et al., 1995). Further, a single injection of a slow-release formulation 
of GBR-12909 produced a prolonged (up to one month) suppression of cocaine self-
administration in nonhuman primates (Glowa et al., 1996). These findings support GBR-
12909 as a potential candidate for the treatment of cocaine addiction (Rothman et al., 2008).  
Clinical trials: GBR-12909 was investigated in clinical trials at NIDA and University of Texas 
from 2003 to 2008 (Table 1). However, the appearance of cardiovascular side-effects has 
prevented its further development as an anti-cocaine medicine at NIDA, NIH (Vocci and 
Elkashef, 2005).  
2.2 RTI-336 
Preclinical studies: RTI-336 is a novel DAT inhibitor of the 3-phenyltropane class and has a 
slower-onset (30 min vs. < 10 min) longer-acting (4 hrs vs. 1-2 hrs) profile than cocaine 
(Carroll et al., 2006; Kimmel et al., 2007). It has >1000- and >400-fold selectivity for  
DAT over serotonin transporter (SERT) and norepinepherine transporter (NET), respectively 
(Carroll et al., 2006). Pretreatment with RTI-336 produced a dose-dependent reduction in 
cocaine self-administration in both rats and nonhuman primates (Haile et al., 2005; Howell 
et al., 2007). The ED50 dose of RTI-336 for reducing cocaine self-administration resulted in 
approximately 90% DAT occupancy, suggesting that high levels of DAT occupancy by RTI-
336 are required to reduce cocaine self-administration. However, co-administration of the 
ED50 dose of RTI-336 with the SERT inhibitors fluoxetine or citalopram produced more 
robust reductions in cocaine self-administration in non-human primates than RTI-336 alone 
(Howell et al., 2007), suggesting that blockade of both DAT and SERT may be more effective 
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in attenuating cocaine’s reinforcing effects than selective blockade of DAT alone (Rothman 
et al., 2007). In addition, at the doses that effectively suppressed cocaine self-administration, 
RTI-336 also inhibited food-taking behavior (Howell et al., 2007). This differs from GBR-
12909, which selectively inhibits cocaine self-administration but not food-taking behavior. 
RTI-336, like many other DAT inhibitors, reliably maintained self-administration behavior 
in all non-human primates tested (Howell et al., 2007) and produced locomotor stimulating 
effects in mice and rats, suggesting abuse potential by itself. However, compared to cocaine, 
RTI-336 maintained lower rates of responding and lower progressive-ratio (PR) break-points 
in the self-administration paradigm. It also produced weaker locomotion hyperactivity and 
drug discriminative stimulus effects, and showed very low sensitization in locomotion 
(Carroll et al., 2006; Czoty et al., 2010). These data suggest that RTI-336 may have lower 
abuse potential than cocaine. 
Clinical trials: RTI-336 has been investigated in Phase I clinical trials at RTI International 
(NC, USA) and NIDA (MD, USA) since 2008 (Table 1). It was a double-blind, placebo-
controlled Phase I study to evaluate the safety, tolerability, and pharmacokinetics of RTI-336 
in healthy, male subjects. The study has been completed, but not yet reported. 
 
Compound Company Pharmacology Indication Status Reference 
GBR-12909 Antia Lab., 
China; 
Others 
DAT inhibitor Safety and PK 
profiles; 
Cocaine addiction 
Phase I, 
terminated 
at NIDA in 
2008 
http://clinica
ltrials.gov 
RTI-336 RTI, NC, 
USA 
DAT inhibitor Safety, tolerability & 
PK profiles 
Phase I, http://clinica
ltrials.gov 
Methylpheni
date 
Shire US, 
Dublin, 
Ireland 
DAT inhibitor Substance Abuse 
(cocaine, 
methamphetamine) 
Phase II http://clinica
ltrials.gov 
Modafinil Cephalon, 
PA, USA 
DAT inhibitor; 
Glutamate 
enhancer; 
GABA inhibitor
Drug Addiction 
(cocaine, 
methamphetamine 
 
Schizophrenia 
Phase II 
 
 
 
Phase IV 
http://clinica
ltrials.gov 
Disulfiram LKT Lab., 
MN, USA 
Aldehyde 
dehydrogenase 
inhibitor; 
 
Dopamine-β-
hydroxylase 
inhibitor 
Substance Abuse 
(cocaine, heroin or 
methamphetamine)
 
Others 
Phase III http://clinica
ltrials.gov 
Table 1. DAT- or DA-related drug candidates in clinical trials 
2.3 CTDP-31,345 
Based upon the above finding that a combination of DAT and SERT inhibitors appears to be 
more potent and effective than DAT inhibitor alone in attenuation of cocaine self-
administration (Howell et al., 2007), we studied slow-onset long-acting monamine transporter 
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(MAT) inhibitors that have higher affinity for both DAT and SERT over to NET. In addition, 
our interest in non-selective MAT inhibitors as potential anti-cocaine medications originally 
stems from the fact that cocaine is also a non-selective MAT inhibitor. Thus, it was 
hypothesized that a ‘cocaine-like’ MAT inhibitor with slow-onset and long-acting profiles 
would be able to substitute for cocaine for the treatment of cocaine dependence (Peng et al., 
2010c). CTDP-31,345 is such a MAT inhibitor with slow-onset (30-60 min) long-acting (at least 
6 hrs) (Peng et al., 2010c) and with higher selectivity for DAT and SERT over NET (Ki = 18, 23 
and 81 for DAT, SERT and NET, respectively) (Froimowitz et al., 2000). The “CTDP” 
terminology derives from the “Cocaine Treatment Discovery Program” of the NIDA 
Extramural Program. Structurally, it is a trans-aminotetralin derivative (Peng et al., 2010c). It is 
a prodrug, which is metabolized (N-demethylated) to CTDP-31,346, a slow-onset long-acting 
MAT inhibitor. Pretreatment with a single dose of CTDP-31,345 produced a dose-dependent 
long-term (24-48 h) reduction in cocaine self-administration in rats (Peng et al., 2010c). CTDP-
31,345 itself appears to have lower abuse liability than cocaine because it produces weaker 
brain-stimulation reward and maintains a lower rate of self-administration than cocaine (Peng 
et al., 2010c). In addition, systemic administration of CTDP-31,345 produces moderate, but 
long-lasting, increases in NAc DA, which may translate to decreases in drug craving and 
relapse by restoring reduced synaptic DA in brain reward circuits (Volkow et al., 1999). CTDP-
31,345 is not currently in clinical trials.  
2.4 Methylphenidate 
Preclinical studies: Methylphenidate is a FDA-approved DAT inhibitor for the treatment of 
attention deficit hyperactivity disorder (ADHD). It binds to presynaptic DAT and NET, but 
not to SERT, blocking DA and NE re-uptake and increasing synaptic DA and NE (Leonard 
et al., 2004). Methylphenidate is self-administered in rodents, and pretreatment with 
methylphenidate significantly shifts the cocaine self-administration dose-response curve to 
the left (Hiranita et al., 2009, 2011), suggesting that methylphenidate has cocaine-like abuse 
potential and produces additive effects in combination with cocaine.  
Clinical trials: ADHD has high comorbidity with cocaine-dependent patients as much as 30% 
in some studies (Schubiner et al., 2000). Because of this, its therapeutic effects for the 
treatment of cocaine addiction in this population have been recently evaluated in clinical 
trials (Table 1). Placebo-controlled studies produced mixed results with one study reporting 
no effect (Schubiner et al., 2002) while three studies demonstrating a significant reduction in 
both cocaine use and the positive subjective effects of cocaine compared to placebo 
(Winhusen et al., 2006; Collins et al., 2006; Levin et al., 2007). Because the half-life of 
methylphenidate is short (2-3 hrs in humans), the drug has been made available in 
sustained-release formulations in addition to the traditional immediate-release formulation. 
The sustained-release methylphenidate displayed much lower abuse potential than 
immediate-release, and appears to be more effective than immediate-release in decreasing 
cocaine use and the positive subjective effects (Arria and Wish, 2006; White et al., 2006).  
2.5 CTDP-32,476 
Based on the aforementioned findings of sustained-release methylphenidate in clinical trials, 
we have recently developed a series of methylphenidate analogs with slow-onset long-acting 
profiles as medication candidates for the treatment of cocaine addiction. CTDP-32,476 is a 
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representative compound in this drug category. Structurally, CTDP-32,476 is a metabolically 
stable methylphenidate analog, in which the metabolically unstable ester moiety of 
methylphenidate is removed from methylphenidate’s structure (Froimowitz et al. 2007). In 
vitro binding assays suggest that CTDP-32,476 is a selective DAT inhibitor with ~50-fold and 
~350-fold selectivity for DAT over NET and SERT (Ki= 16, 5900 and 840 nM for DAT, SERT 
and NET, respectively) (Froimowitz et al., 2007). Functional reuptake assays reveal that CTDP-
32,476 has IC50 values of 8.6, 490 and 120 nM for inhibition of DA, 5-HT and NE reuptake, 
respectively. In addition, it also displays approximately 30-fold higher affinity for the DAT 
than cocaine (Ki: 16 vs. 500 nM; IC50: 8.6 vs. 244 nM) (Froimowitz et al., 2007). Systemic 
administration of CTDP-32,476 produced a slow-onset (20-60 min) long-term (6-12 hrs) 
increase in locomotion and extracellular DA in the NAc (Xi et al., 2009). Pretreatment with 
CTDP-32,476 significantly and dose-dependently inhibited intravenous cocaine self-
administration under both FR and PR reinforcement, shifted the cocaine dose-response self-
administration curves downward and to the right, and attenuated cocaine-induced increases 
in locomotion and extracellular DA in the NAc (Xi et al., 2011a). These data suggest that 
pretreatment with CTDP-32,476 produced functional antagonism of cocaine’s action, likely by 
attenuating cocaine’s binding to DAT. CTDP-32,476 itself appears to have much lower 
addictive potential than cocaine. Drug naïve rats selectively self-administer cocaine, but not 
CTDP-32,476. In rats trained to self-administer cocaine, CTDP-32,476 maintained significantly 
lower rates of self-administration and lower PR break-points than cocaine. Taken together, 
these data suggest that CTDP-32,476 appears to be an excellent agonist therapy for cocaine 
dependence. CTDP-32,476 has not been tested in human clinical trials. 
2.6 Modafinil 
Preclinical studies: Modafinil is a wake-promoting drug used in the clinic for the treatment of 
narcolepsy and idiopathic hypersomnia (Wise et al., 2007). However, the neurochemical 
mechanisms underlying modafinil’s action are not fully understood. It is reported that 
modafinil increases extracellular levels of glutamate in numerous brain regions including 
striatum, thalamus, hippocampus, and hypothalamus (Ballon and Feifel, 2006; Wise et al., 
2007). In addition, it also inhibits brain GABA release (Ballon and Feifel, 2006). Recent 
studies suggest that modafinil is a DAT inhibitor in humans and primates (Madras et al., 
2006; Volkow et al., 2009). This is further supported by the findings that mice lacking DAT 
or DA (D1 and D2) receptors do not respond to the wake-promoting effects of modafinil (Qu 
et al., 2008; Wisor et al., 2001). In vivo microdialysis studies demonstrated that modafinil 
increases extracellular DA (Wisor et al., 2001; Ferraro et al., 1997; Murillo-Rodríguez et al., 
2007). Neuroimaging studies in both non-human primates and healthy human subjects 
demonstrated significant occupancy of DAT (and also NET) by intravenously-administered 
modafinil (Madras et al., 2006; Volkow et al., 2009). Consistent with these findings, 
modafinil has been shown to have weak cocaine-like discriminative and reinforcing effects 
in both rodents and non-human primates (Gold and Balster., 1996; Deroche-Gamonet et al., 
2002), and weak stimulant-like subjective effects in humans (Kruszewski, 2006; O'Brien et 
al., 2006). Based on these recent findings, modafinil is categorized as a DAT-based ‘agonist 
therapy’ for cocaine dependence.  
Clinical studies:  Dackis et al (2003) first reported that modafinil's stimulant-like activity may 
diminish the symptoms of cocaine withdrawal, including hypersomnia, lethargy, dysphoric 
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mood, cognitive impairment, and increased appetite, thereby reducing the desire to use 
cocaine. The first randomized, double-blind clinical trial involved 62 cocaine-dependent 
outpatients who received either a single dose of modafinil or placebo daily for 8 weeks 
(Dackis et al., 2005). Patients treated with modafinil had significantly less cocaine use than 
patients treated with placebo (Hart et al., 2008). No significant adverse effects were noted. 
The therapeutic effects of modafinil in cocaine users have been supported by a recently 
completed multi-site, placebo-controlled clinical trial involving 210 cocaine-dependent 
outpatients (Anderson et al., 2009). Currently, more than 10 additional clinical trials are 
under way to further evaluate the efficacy of modafinil treatment for cocaine addiction 
(Table 1).  
2.7 Disulfiram  
Preclinical studies: Although disulfiram is not a DAT inhibitor, I list it under this treatment 
category because it elevates extracellular DA by inhibiting DA metabolism, producing 
effects similar to DAT inhibitors. In 1937, disulfiram was first reported as a potential 
treatment for alcoholism by Williams, a plant physician in a chemical company. 
Unexpectedly, Williams observed that after exposure to disulfram, his laboratory assistants 
could not drink alcohol in any form because alcohol produced a series of unwanted effects 
such as flushing, sweating, headaches, nausea, tachycardia, palpitations, arterial 
hypotension and hyperventilation (Williams, 1937). Since then, disulfiram has been used in 
the treatment of alcoholism for more than half a century (Suh et al., 2006; Barth and 
Malcolm, 2010). Disulfiram is an inhibitor of aldehyde dehydrogenase, the enzyme that 
transforms acetaldehyde into acetate during alcohol metabolism (Weinshenker, 2010). When 
a person drinks alcohol while taking disulfiram, the resulting acetylaldehyde accumulation 
causes an aversive reaction as described above, which discourages further drinking. In 
addition, disulfiram also inhibits dopamine-β-hydroxylase (DBH) (Weinshenker, 2010), the 
enzyme that transforms DA into norepinephrine. Such DBH inhibition would increase brain 
DA levels while decreasing brain NE release. This effect could be therapeutic for cocaine 
dependence since an increase in brain DA may be helpful in attenuating withdrawal 
syndromes and craving (Volkow et al., 1999), while a decrease in NE may be helpful in 
attenuating relapse to drug use (Smith and Aston-Jones, 2008; Weinshenker, 2010). In 
experimental animals, disulfram stimulates DA release and potentiates cocaine-induced 
increases in extracellular DA in the prefrontal cortex (Devoto et al., 2011). It also facilitates 
the development and expression of locomotor sensitization to cocaine in rats (Haile et al., 
2003). However, in animal models of relapse, pretreatment with disulfram attenuates 
cocaine-induced reinstatement of drug-seeking behaviour (Schroeder et al., 2010). 
Clinical trials:  The initial impetus for the use of disulfiram to treat cocaine dependence was 
the high rate of comorbidity between cocaine abuse and alcohol abuse (Gossop and Carroll, 
2006). Thus, it was hypothesized that a reduction in alcohol use would lead to secondary 
reduction in cocaine use. Additionally, abstinence from alcohol would prevent formation of 
cocaethylene, a metabolite formed when alcohol and cocaine are present together. 
Cocaethylene has pharmacological actions similar to cocaine and increases subjective 
euphoria and heart rate (Hart et al., 2000). Several short-term clinical trials in outpatients 
using both cocaine and alcohol showed that disulfiram, along with cognitive behavioural 
therapy (CBT), significantly reduced cocaine and alcohol use (Carroll et al., 1998; Higgins et 
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al., 1993; Grassi et al., 2007). In one study, the reduction in cocaine use was still present one 
year after treatment (Carroll et al., 2000). An 11-week, double-blind, placebo-controlled trial 
evaluated the efficacy of disulfiram, naltrexone and their combined treatment in 208 patients 
with concurrent cocaine and alcohol dependence. Patients taking disulfiram alone or in 
combination with naltrexone were more likely to achieve combined abstinence from cocaine 
and alcohol than placebo-treated patients (Pettinati et al., 2008). In several randomized, 
placebo-controlled trials, disulfiram seemed to directly reduce cocaine use rather than 
reducing it indirectly by reducing concurrent alcohol use (George et al., 2000; Petrakis et al., 
2000; Carroll et al., 2004). In addition, dilsufiram appears to be effective in attenuating 
cocaine use in comorbid cocaine- and opioid-dependent individuals (Oliveto et al., 2011). As 
a caveat, disulfiram is reported to inhibit cocaine metabolism, and therefore increases 
cocaine plasma levels in humans (Baker et al., 2006). Because of this, it should be used 
cautiously in comorbid cocaine and alcohol patients with severe cardiovascular diseases 
(Malcolm et al., 2008). 
3. Dopamine receptor-based antagonist therapies 
Rationale: Cocaine’s action is largely mediated by elevation of extracellular DA that activates 
postsynaptic DA receptors. Thus, blockade of DA receptors is a plausible therapeutic 
approach for cocaine addiction (Figure 2). There are five DA receptor subtypes identified in 
the brain that are classified as D1-like (D1, D5) and D2-like (D2, D3, D4) based on their 
pharmacological profile (Beaulieu and Gainetdinov, 2011). Although both D1 and D2 
receptor subtypes have been shown to play predominant roles in mediating actions of DA, 
clinical trials with selective D1 or D2 receptor antagonists for the treatment of cocaine 
addiction have failed due to ineffectiveness and/or unwanted side-effects such as sedation 
and extra pyramidal locomotor syndromes (see review by Platt et al., 2002; Gorelick et al., 
2004). In response, efforts have increased to develop relatively low selective D1/2 receptor 
antagonists or D3 receptor-based antagonist therapies for cocaine dependence.  
3.1 Levo-tetrahydropalmatine (l-THP) 
Preclinical studies: Tetrahydropalmatine (THP) is a tetrahydroprotoberberine (THPB) 
isoquinoline alkaloid and a primary active constituent of the herbal plant species Stephania 
rotunda Lour and Corydalis ambigua (Yanhusuo) (Jin et al., 1987). The levo-isomer of THP (l-
THP) has been shown to contribute to many of the therapeutic effects of these herbs such as 
sedative, neuroleptic and analgesic effects (Chu et al., 2008; Jin, 1987). Purified or synthetic l-
THP has been approved in China as a traditional sedative-analgesic agent for the treatment 
of chronic pain and anxious insomnia for more than 40 years. Pharmacologically, l-THP is a 
non-selective DA receptor antagonist with roughly 3-fold selectivity for D1 versus D2 
receptor and 10-fold selectivity for D1 versus D3 receptor (Ki = 124, 388, or 1420 nM for D1, 
D2, or D3 receptors, respectively) (Wang and Mantsch, 2012). In addition, it has moderate 
binding affinity to alpha (α1, α2A) adrenergic and 5-HT1A (Ki = 340 nM) receptors. Because 
cocaine is a non-selective MAT inhibitor, which increases brain DA, NE and 5-HT levels, it 
was hypothesized that blockade of multiple DA, adrenergic and 5-TH1A receptors by l-THP 
would functionally antagonize cocaine’s action (Mantsch et al., 2007; Xi et al., 2007). In 
support of this hypothesis, l-THP was found to significantly inhibit intravenous cocaine self-
administration under FR and PR reinforcement schedules (Mantsch et al., 2007, 2010; Xi et 
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al., 2007), cocaine-induced conditioned place preference (CPP) (Luo et al., 2003), cocaine-
enhanced electrical brain-stimulation reward (Xi et al., 2007), and cocaine-, cue- or stress-
induced reinstatement of drug-seeking behaviour in rats (Mantsch et al., 2007, 2010; 
Figueroa-Guzman et al., 2011). These anti-cocaine effects are unlikely due to l-THP-induced 
sedation or locomotor impairment, since the effective doses that decrease cocaine’s effects 
are much lower (3-10 fold) than those that produce locomotion inhibition (Xi et al., 2007). 
These data suggest that l-THP may have therapeutic potential for treatment of cocaine 
addiction in humans.  
Clinical studies: A pilot study examined the efficacy of l-THP in reducing craving and relapse 
in 120 heroin addicts (Yang et al., 2008). In this randomized, double-blind, placebo-
controlled study, patients received 4 weeks of l-THP treatment and three months follow-up 
after l-THP treatment. The results showed that l-THP significantly lowered opiate 
withdrawal symptoms and craving and increased abstinence rate. Another study examined 
the therapeutic effect of l-THP combined with methadone for heroin detoxification (Hu et 
al., 2006), and found that l-THP, combined with methadone, significantly elevated 
detoxification rate, lowered total amount of methadone and decreased time for the 
detoxification. L-THP is being investigated in human clinical trial for the treatment of 
cocaine addiction in University of Maryland, Baltimore (Table 2).  
 
Compound Company Pharm. Action Indication Status Reference 
L-THP Best & Wide, 
Nanning, 
China 
D1/D2/D3 
Antagonist 
Drug abuse 
(heroin, cocaine) 
Phase I, 
Phase II 
Yang et al., 2008; 
Wang & Mantsch, 
2012 
BP-897 Bioproject, 
Paris, France 
D3 Partial 
Agonist 
Safety Study Phase II Garcia-Ladona & 
Cox, 2003 
Cariprazine Gideon 
Richter, 
Budapest, 
Hungary 
D3-Partial 
Agonist 
Bipolar disorder; 
Schizophrenia 
Phase III http://clinicaltrials
.gov 
ABT-925 Abbott, IL, 
USA 
D3 Antagonist Schizophrenia Phase II http://clinicaltrials
.gov 
ABT-614 Abbott, IL, 
USA 
D3 Antagonist PK properties 
D3R binding by 
PET 
Phase I http://clinicaltrials
.gov 
GSK598809 GSK, 
Uxbridge, UK 
D3 Antagonist Substance abuse 
(nicotine); 
Food reward 
Phase II http://clinicaltrials
.gov 
GSK618334 GSK, 
Uxbridge, UK 
D3 Antagonist Substance abuse 
(alcoholism) 
Phase I http://clinicaltrials
.gov 
S33138 Institut de 
Recherches 
Servier, 
Croissy sur 
Seine, France 
D3-Preferring 
Antagonist 
D3R binging by 
PET; 
Safety 
Phase I Thomasson-Perret 
et al., 2008; 
Millan et al., 2008 
Table 2. DA receptor-based drug candidates in clinical trials 
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3.2 BP-897  
Preclinical studies: BP-897 is the first developed D3-selective partial agonist (Pilla et al., 1999) 
or antagonist (Wicke and Garcia-Ladona, 2001). A series of studies have assessed the 
efficacy of BP-897 in animal models of drug addiction (see reviews by Garcia-Ladona and 
Cox, 2003; Le Foll et al., 2005; Heidbreder et al., 2005). BP-897 produces a dose-dependent 
decrease in cocaine self-administration under second-order reinforcement, cocaine-induced 
CPP, cocaine’s discriminative stimulus properties, and cocaine- or cue-induced 
reinstatement of cocaine-seeking behaviour. These data support the potential use of BP-897 
in the treatment of cocaine addiction, particularly in relapse to drug-seeking behavior.  
Clinical trials: BP-897 entered Phase II clinical studies for the treatment of drug addiction in 
the early 2000s. However, the detailed results about its safety, pharmacokinetics and 
therapeutic efficay have not yet been reported.  
3.3 Cariprazine 
Preclinical studies: Cariprazine (RGH-188) is a novel D3 receptor partial agonist with 10-fold 
selectivity for D3 over D2 (Gründer, 2010; Kiss et al., 2010). It is also a weak 5-HT1A and 5-
HT5C partial agonist. Although limited preclinical data are available, the ‘concept-proven’ 
finding with BP-897 suggests that cariprazine might be similarly effective in attenuation of 
cocaine’s actions. 
Clinical studies: Cariprazine is currently in Phase III clinical trials for the treatment of 
schizophrenia and bipolar disorder (Table 2). Data from Phase II trials in patients with 
schizophrenia and bipolar mania indicate that the drug has antipsychotic and antimanic 
properties that are superior to placebo. The efficacy of cariprazine for treatment of cocaine 
addiction has not been evaluated.  
3.4 SB-277011A  
Preclinical studies: SB-277011A is the most well-characterized D3 receptor antagonist in 
preclinical animal models of drug addiction to date (Heidebreder et al., 2005; Heidbreder 
and Newman, 2010). SB-277011A has high affinity for human D3 receptor, and the 
selectivity for human and rat D3 over D2 receptor is 120 and 80, respectively (Reavill et al., 
2000). In experimental animals, SB-277011A significantly and dose-dependently attenuates 
cocaine-enhanced brain-stimulation reward (Vorel et al., 2002; Spiller et al., 2008), cocaine-
induced CPP (Vorel et al., 2002), cocaine self-administration under PR or FR10 (but not FR1 
or FR2) reinforcement (Xi et al., 2005), and reinstatement of drug-seeking behavior caused 
by cocaine priming, cue or footshock stress (Vorel et al., 2002; Xi et al., 2004b; Gilbert et al., 
2005). In addition, systemic administration or intracranial microinjections into the NAc or 
basolateral amygdala significantly and dose-dependently inhibited contextual cue-induced 
incubation of cocaine craving in rats (Xi et al., 2012). These data suggest that SB-277011A is a 
promising candidate in medication development for treatment of cocaine addiction.  
Clinical trials: Further development of SB-277011A as a medication for treatment of cocaine 
addiction has been halted by GlaxoSmithKline Pharmaceuticals, due to unexpected poor 
bioavailability (~2%) and a short half-life (<20 min) in primates (Austin et al., 2001; 
Remington and Kapue, 2001). Therefore, much effort has been made to develop other D3-
 
Addictions – From Pathophysiology to Treatment 
 
322 
selective antagonists with higher bioavailability and more promising pharmacotherapeutic 
profiles (Newman et al., 2005).   
3.5 GSK598809 and GSK618334 
Preclinical studies: Based on the results with SB-277011A, GSK is currently developing other 
D3 receptor antagonists, such as GSK618334 and GSK598809, for the treatment of substance 
abuse and addiction. GSK598809 is a novel, potent and selective DA D3 receptor antagonist 
(Searle et al., 2010). Functional assays showed that GSK598809 has >100-fold selectivity for 
D3 receptors over D2, histamine H1, muscarinic M1, M2, M3, M4, serotonin 5-HT1A, 5-HT1B 
and 5-HT1D receptors (te Beek et al., 2012). CPP experiments in animal models indicated that 
GSK598809 significantly reduced nicotine- and cocaine-seeking behaviour in a dose-
dependent manner (te Beek et al., 2012). In addition, GSK598809 significantly prevented 
relapse to nicotine-seeking behaviour, although no effect was observed on reducing alcohol 
consumption in rats.   
Clinical studies: GSK618334 is currently under Phase I and Phase II clinical trials (Table 2). A 
recent PET imaging study suggests that GSK598809 significantly and dose-dependently 
inhibits [11C]PHNO binding in D3-rich brain regions such as the ventral striatum, globus 
pallidus and substantia nigra (Searle et al., 2010). In healthy volunteers, single doses of 
GSK598809 were generally well tolerated. Plasma concentration of GSK598809 increased 
rapidly after oral administration (Tmax 2-3 hrs) and subsequently decreased in an apparent 
bi-exponential manner (terminal half-life of roughly 20 hrs). The CNS effects of GSK598809 
alone were limited to elevation of serum prolactin and a small decrease in adaptive tracking 
performance (te Beek et al., 2012).  GSK598809, at a dose (175 mg) that associated >90% D2/3 
receptor occupancy, appeared to have no overall effect on attention bias to food-related cues 
(as measured behaviorally) (Nathan et al., 2011), on subjective hunger or craving ratings and 
on brain response to food images (as measured by fMRI) in overweight and obese binge 
eating individuals (Dodds et al., 2012). These findings are consistent with previous findings 
in experimental animals demonstrating that SB-277011A or NGB-2904 have no significant 
effects on food-induced CPP and food-taking behavior (Vorel et al., 2002; Ross et al., 2007; 
Thanos et al., 2008). Contrary to the promising finding in experimental animals, a recent 
clinical trial with GSK598809 for the treatment of alcoholism demonstrated that it produces 
an additive, not an expected inhibitory, effect on alcohol intake (te Beek et al., 2012). 
GSK598809 is currently under Phase II clinic trial for treatment of nicotine dependence 
(http://clinicaltrials.gov/).  The effects of GSK598809 on cocaine dependence have not yet 
been evaluated.  
3.6 ABT-925 
ABT-925, also known as A-437203 or BSF-201640, is a selective D3 receptor antagonist 
developed by Abbott Laboratories. It has an approximately 100-fold selectivity for D3 versus 
D2 receptors (Geneste et al., 2006). Although the preclinical data for this compound are 
currently unavailable, proof-of-concept for D3 receptor antagonists in treatment of 
schizophrenia and drug abuse has been well-estabolished. In Phase I and Phase II clinical 
trials (Table 2), ABT-925 was safe and generally well tolerated up to the highest dose levels 
tested (600 mg single dose, 500 mg once daily for 7 days) (Day et al., 2010; Graff-Guerrero et 
al., 2010; Redden et al., 2011). However, a recent double-blind, placebo-controlled study for 
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the treatment of acute schizophrenia suggest that ABT-925, at 50-150 mg per day, did not 
produce statistically significant therapeutic effects compared to placebo (Redden et al., 
2011).  
3.7 NGB-2904 
NGB-2904 is another highly selective D3 receptor antagonist with >150-fold or 800-fold 
selectivity for primate or rat D3 over D2 receptors and 5000-fold selectivity for D3 over D1, 
D4, and D5 receptors (Yuan et al., 1998). Based upon its high selectivity for DA D3 receptors, 
we have recently evaluated the pharmacological effects in animal models of drug addiction. 
We found that systemic administration of NGB-2904 dose-dependently inhibits cocaine self-
administration under PR (but not FR2) reinforcement (Xi et al., 2006b), cocaine-enhanced 
electrical brain reward function (Xi et al., 2006b; Spiller et al., 2008), and cocaine- and 
cocaine cue-induced reinstatement of cocaine-seeking behavior (Gilbert et al., 2005; Xi et al., 
2006b). NGB-2904 alone neither produces dysphorigenic effects in brain-stimulation reward 
nor substitutes for cocaine in self-administration, suggesting that NGB-2904 itself has no 
abuse potential (Xi and Gardner, 2007). NGB-2904 is not currently under clinical trials, and 
detailed data regarding bioavailability and pharmacokinetic properties are presently 
unavailable.  
3.8 YQA-14 
YQA-14 is a novel D3 receptor antagonist developed recently (Song et al., 2012). 
Structurally, YQA-14 is a NGB-2904 analog. In vivo pharmacokinetic assays suggest that 
YQA-14 has improved oral bioavailability (>40%) and a longer half-life (>6 h in humans) 
compared to SB-277011A (~20 min in primates). In experimental animals, YQA-14 dose-
dependently inhibits cocaine self-administration under both FR2 and PR reinforcement 
schedules, cocaine-induced CPP, cocaine-enhanced brain-stimulation reward, and cocaine- 
or cue-induced reinstatement of drug-seeking behavior (Song et al., 2012). Strikingly, at the 
doses that inhibit cocaine’s actions, YQA-14 failed to alter oral sucrose self-administration 
and locomotor activity. YQA-14 is neither self-administered in drug-naïve rats nor 
substitutes for cocaine in maintenance of self-administration in rats previously trained for 
cocaine self-administration, suggesting that YQA-14 itself has no abuse liability. Deletion of 
DA D3 receptors in D3-knockout mice almost completely abolished the inhibitory effect by 
YQA-14 of cocaine self-administration, suggesting an effect mediated by blocking DA D3 
receptors in vivo (Song et al., 2012). YQA-14 is currently not under clinical trials.  
3.9 S33138 
Preclinical studies: S33138 is a preferential D3 versus D2 receptor (~25-fold selectivity) 
antagonist (Millan et al., 2008). It was hypothesized that blockade of D3 plus partial blockade 
of D2 receptors may produce additive anti-cocaine therapeutic effects, but have fewer 
unwanted side-effects such as sedation and extrapyramidal locomotor impairment due to 
partial blockade of D2 receptors (Peng et al., 2009). In experimental animals, we found that 
S33138 produced biphasic effects – low doses increase, while high doses inhibit, cocaine self-
administration under FR2 reinforcement. We interpret this increase in cocaine self-
administration as a compensatory response to a reduction in cocaine’s rewarding efficacy at 
low doses. In addition, S33138 also dose-dependently inhibits cocaine-enhanced brain-
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stimulation reward and cocaine-induced reinstatement of drug-seeking behavior (Peng et al., 
2009). S33138, at low-to-moderate doses, has no effect on brain reward function by itself, while 
at high doses, produces an aversive-like effect as assessed by electrical brain-stimulation 
reward experiments, suggesting a D2 receptor-mediated effect at high doses. Further high 
doses of S33138 also inhibit oral sucrose self-administration, suggesting possible unwanted 
effects on nature reward at high doses.  
Clinical trials: S33138 is currently under clinical trials as an anti-psychotic agent for the 
treatment of schizophrenia and other psychiatric diseases (Millan and Brocco, 2008; 
Thomasson-Perret et al., 2008). The efficacy of S33138 for treatment of cocaine addiction has 
not been evaluated in human clinical trials.  
4. Glutamate-based medication strategies 
Rationale: L-glutamate is the major excitatory neurotransmitter in the brain and acts through 
two heterogeneous families of glutamate receptors: ionotropic (iGluR) and metabotropic 
(mGluR) glutamate receptors. While iGluRs (i.e. NMDA, AMPA and kainite) are ligand-
gated ion channels and responsible for fast excitatory neurotransmission, mGluRs (mGluR1-
8) are G-protein-coupled receptors linked to intracellular second messenger pathways. The 
eight subtypes of mGluRs have been classified into three groups on the basis of sequence 
similarities and pharmacological properties. Group I (mGluR1,5) receptors activate 
phospholipase C via Gq proteins, whereas group II (mGluR2,3) and group III (mGluR4,6,7,8) 
receptors inhibit adenylate cyclase via Gαi/o proteins (see review by Cartmell and Schoepp, 
2000). 
Although the role of glutamate in mediating cocaine’s rewarding effects remains unclear 
(see review by Xi and Gardner, 2008), growing evidence suggests that glutamate is critically 
involved in relapse to drug-seeking behavior (Figure 3) (Kalivas, 2009; Bowers et al., 2010). 
In brief, chronic cocaine produces a reduction in basal levels of extracellular glutamate or 
glutamate transmission in the NAc during cocaine withdrawal, while cocaine priming or re-
exposure to cocaine-associated cues stimulate glutamate release in both the VTA and NAc. 
These findings suggest that both a reduction in basal glutamate transmission and enhanced 
glutamate responding to cocaine or cocaine-associated cues may constitute a neurobiological 
substrate of relapse to drug-seeking behavior (Kalivas, 2009). Based on this hypothesis, a 
number of pharmacotherapeutic strategies have been proposed. These include, first, 
normalization (increase) of reduced basal glutamate neurotransmission during abstinence, 
and second, antagonism of enhanced glutamate responses to cocaine or cocaine-associated 
cues (Figure 3).  
4.1 N-acetylcysteine 
Preclinical studies: N-acetylcysteine (NAC) is a cystine prodrug. It is approved for the 
treatment of pulmonary complications of cystic fibrosis and paracetamol (acetaminophen) 
overdose. By providing a source of extracellular cysteine, which is converted to cystine, 
NAC can exchange extracellular cystine for intracellular glutamate. This restores 
(renormalizes) decreased basal levels of extracellular glutamate (Baker et al., 2003). The 
increased extracellular glutamate may subsequently attenuate cocaine-induced increases in 
glutamate release by activation of presynaptic mGluR2/3 receptors, and therefore inhibits 
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cocaine- or cocaine cue-induced reinstatement of drug-seeking behaviour (Figure 3). NAC 
did not decrease cocaine self-administration or acute cocaine-induced hyperactivity, while it 
decreased repeated cocaine-induced escalation of drug intake and behavioural sensitization 
(Madayag et al., 2007). In addition, repeated NAC treatments also attenuated cocaine-
induced increases in drug seeking in rats (Baker et al., 2003; Amen et al., 2010). Interestingly, 
NAC is also a prodrug for the synthesis of the endogenous antioxidant glutathione, and that 
NAC pretreatment protects animals from high dose methamphetamine- or amphetamine-
induced DA neurotoxicity and behavioural changes by lowering oxidative stress levels 
(Fukami et al., 2004; Achat-Mendes et al., 2007).  
Clinical trials: NAC is currently under clinical trials (Table 3). In double-blind, placebo-
controlled clinic trials, NAC was well tolerated and produced a significant reduction in 
cocaine-related withdrawal symptoms and/or cravings triggered by exposure to cocaine-
related cues or by an experimenter-delivered intravenous injection of cocaine (LaRowe et al., 
2006, 2007; Amen et al., 2010). A 4-week open-label clinical trial demonstrated that NAC 
significantly reduced cocaine use in 16 of 23 human cocaine-dependent subjects (Mardikian 
et al., 2007). More clinical trials are currently underway (http://clinicaltrials.gov/).  
 
Compound Company Pharm. Action Indication Status Reference 
N-acetylcysteine 
(NAC) 
TwinLab, 
NY, USA; 
Others 
Cystine prodrug Substance abuse 
(cocaine, nicotine, 
methamphetamine) 
Phase II http://clinicaltrials.
gov 
AZD8529 AntraZeneca, 
London, UK 
mGluR2/3 PAM Schizophrenia Phase II http://clinicaltrials.
gov 
ADX71149 Janssen, USA mGluR2 PAM Schizophrenia; 
Anxiety 
Phase II http://www.addex
pharma.com/piplin
e/ 
LY214023 Eli Lilly, USA mGluR2/3 PAM PK study Phase I http://clinicaltrials.
gov 
LY404039 Eli Lilly, USA mGluR2/3 PAM Schizophrenia Phase II Patil et al., 2007 
LY354740 Eli Lilly, USA mGluR2 PAM Schizophrenia; 
Anxiety 
Phase II Dunayevich et al., 
2008 
JNJ-40411813 Johnson & 
Johnson, 
USA 
mGluR2 PAM Schizophrenia Phase II http://clinicaltrials.
gov 
GPI-5633 Guiford,  
USA 
mGluR3 PAM Safety & PK profile Phase I Van der Post et al., 
2005 
Fenobam Enzo Life Sci. 
USA;  Others
mGluR5 NAM Anxiety; 
Fragile X syndrome 
Phase II http://clinicaltrials.
gov 
ADX10059 Addex 
Switzerland 
mGluR5 NAM Gastro-oesophageal 
reflux 
Phase II http://clinicaltrials.
gov 
STX107 
 
Seaside, 
USA 
mGluR5 NAM Fragile X Syndrome Phase II http://clinicaltrials.
gov 
Table 3. Glutamate-based drug candidates in clinical trials 
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Fig. 3. Schematic diagram of glutamatergic synaptic transmission in the NAc, illustrating 
that cocaine priming or re-exposuse to cocaine-associated cues evokes an increase in 
glutamate release and relapse to drug-seeking behaviour in rats. Various compounds that 
target CB1 and mGluRs may attenuate cocaine- or cue-induced increase in glutamate release 
or in postsynaptic glutamate receptor signalling, and therefore, inhibit relapse to drug-
seeking behaviour. 
4.2 MPEP  
Preclinical studies: MPEP is a selective mGluR5 negative allosteric modulator (NAM) or 
antagonist (Gasparini et al., 1999). The first study to examine the role of mGluR5 in drug 
addiction reported that deletion of mGluR5 subtype abolishes cocaine self-administration in 
mice, while systemic administration of MPEP significantly inhibited cocaine self-
administration in mice (Chiamulera et al., 2001). Since then, a large number of studies 
suggest that systemic administration of MPEP or its analog MTEP (a more selective mGluR5 
NAM) (Lea and Faden, 2006) significantly and dose-dependently inhibits cocaine self-
administration in rats (Xi et al., 2004a, 2004c; Tessari et al., 2004; Paterson and Markou, 2005; 
Kenny et al., 2005; Lee et al., 2005), cocaine-induced CPP (McGeehan and Olive, 2003; Herzig 
and Schmidt, 2004), cocaine-induced hyperactivity (McGeehan  et al., 2004), and cocaine-, 
cue- or stress-induced reinstatement of cocaine-seeking behaviour (Xi et al., 2004a, 2004c; 
Lee et al., 2005; Backstrom and Hyytia, 2006; Kumaresan et al., 2009; Martin-Fardon and 
Weiss, 2011; Wang et al., 2012). These data strongly suggest that mGluR5 antagonists may 
be promising in the treatment of cocaine addiction.  
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Clinical trials: MPEP and MTEP have not been tested in clinical trials. Relatively poor 
selectivity of MPEP for mGluR5 over other targets (NET, NR2B-containing NMDA receptor, 
monoamine oxidase A and mGluR4) may have prevented its use in human clinical trials.  
4.3 Fenobam 
Preclinical studies: Fenobam (McN-3377) was originally developed as a nonbenzodiazepine 
anxiolytic in the 1980s with an unknown molecular target until 2005 when it was reported 
that fenobam is a selective mGluR5 NAM or antagonist (Porter et al., 2005). Fenobam was 
reported to have improved mGluR5 selectivity compared to MPEP, as assessed by the use of 
mGluR5-KO mice, and rapidly penetrate brain-blood barrier to concentrate in the brain 
(Montana et al., 2009). Systemic administration of fenobam dose-dependently elevates 
stimulation threshold for brain-stimulation reward in rats, suggesting a reduction in brain 
reward function (Cleva et al., 2012). In addition, our pilot experimental data also suggest 
that oral administration of fenobam significantly inhibits cocaine self-administration and 
cocaine- or cue-, induced cocaine-seeking behaviour. 
Clinical trials: Fenobam was investigated in Phase II clinical trials in the 1980s for the 
treatment of anxiety and depression (Table 3). Earlier single- or double-blind, placebo-
controlled clinical trials demonstrated that fenobam was effective in attenuating severe 
anxiety with good safety profiles (Pecknold et al., 1982; Pecknold et al., 1980; Lapierre and 
Oyewumi, 1982). However, in another report, it was reported to be inactive and have 
psychostimulant effects by itself (Friedmann et al., 1980). At the time, fenobam was 
discontinued from further development as an anxiolytic.  In 2006, it was granted orphan 
drug designation by the FDA for clinical trials in the treatment of Fragile X syndrome, an 
inherited mental retardation disorder. The efficacy of fenobam in the treatment of cocaine 
addiction has not yet been evaluated. 
4.4 ADX10059 
ADX10059 is another novel mGluR5-selective NAM or antagonist with an IC50 of 17.1 nM at 
human mGluR5, showing good selectivity for mGluR5 over > 65 other receptors, 
transporters, ion channels and enzymes (Marin and Goadsby, 2010). Although limited 
preclinical data are available, it has been under Phase I and Phase II clinical trials for the 
treatment of gastro-oesophageal reflux disease (Zerbib et al., 2010, 2011) and migraine 
(Marin and Goadsby, 2010) (Table 3). To date, ADX10059 has been studied in at least 10 
clinical trials. However, Addex Pharmaceuticals announced the discontinuation of 
development of ADX10059 in December 2009 due to liver enzyme changes. The efficacy of 
ADX10059 in the treatment of cocaine addiction has not been evaluated.  
4.5 LY379268  
Preclinical studies:  LY379268 is a systemically effective mGluR2/3 orthosteric (competitive) 
agonist (Marek, 2004). The mGluR2/3 receptors have become attractive targets in medication 
development for the treatment of drug addiction because mGluR2/3 receptors function as 
glutamate autoreceptors, modulating presynaptic glutamate release (Xi et al., 2002a) (Figure 
3). In addition, mGluR2/3 modulates DA and other neurotransmitter release in the NAc. 
Since cocaine-induced increases in NAc DA and glutamate are critically involved in drug 
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reward and relapse, it was proposed that mGluR2/3 agonists might be useful for the 
treatment of cocaine addiction (Xi et al., 2002a). Systemic administration of LY379268 
inhibits cocaine self-administration and cocaine cue-induced reinstatement of drug-seeking 
behaviour (Baptista et al., 2004; Peters and Kalivas, 2006). Microinjections of LY369268 into 
the NAc or central amygdala also inhibit cocaine- or food-triggered reinstatement of 
reward-seeking behaviour (Peters and Kalivas, 2006) or incubation of cocaine craving in rats 
(Lu et al., 2007). These data suggest that LY369268 may be useful for the treatment of cocaine 
addiction.  
Clinical studies: LY379268 is not currently under clinical trials. This may be related to its 
intrinsic competitive agonist properties that may produce unwanted side-effects by itself 
and/or reduce efficacy due to competitive binding inhibition by excessive glutamate release 
under pathological conditions. In contrast to LY379268, several other mGluR2/3 positive 
allosteric modulators (PAMs) are being investigated in Phase I and Phase II clinical trials for 
the treatment of schizophreria and anxiety (Mezler et al., 2010; Patil., et al., 2007). These 
compounds include AZD8529, LY404039, LY354740, and LY2140023 (Table 3). The potential 
effects of these mGluR2/3 agonists in treatment of cocaine addiction have not been 
evaluated. 
4.6 BINA  
Preclinical studies: Biphenylindanone A (BINA) is a selective mGluR2 PAM or agonist (Johnson 
et al., 2003; Galici et al., 2006).  Recent studies suggest that the pharmacological effects of 
LY379268 (a competitive mGluR2/3 orthosteric agonist) in animal models relevant to 
neuropsychiatric diseases could be mediated predominantly by activation of mGluR2, not 
mGluR3 receptor (Woolley et al., 2008), suggesting that mGluR2-selective agonists may 
produce similar therapeutic effects but have fewer unwanted effects than LY379268. Recently, 
Markou and her colleagues have compared the pharmacotherapeutic effects of BINA and 
LY379268 in animal models of drug addiction. They found that BINA selectively inhibits 
cocaine self-administration and cue-induced reinstatement of cocaine-seeking behaviour 
without affecting behaviours motivated by food reinforcement, while LY379268 nonselectively 
inhibits both cocaine- and food-taking and –seeking behaviour (Jin et al., 2010). These data 
suggest that selective mGluR2 PAMs (BINA) might have better therapeutic potential than dual 
mGluR2/3 agonists (LY379268) for the treatment of cocaine addiction. 
Clinical trials: BINA is currently not under clinical trials. However, other mGluR2 PAMs 
such as AZD71149, LY354740 and JNJ-40411813 are currently under clinical trials for safety 
and in vivo binding property in healthy volunteers (Table 3).  
4.7 2-PMPA and GPI-5693 
Preclinical studies: 2-PMPA and GPI-5693 (also called 2-MPPA) are inhibitors of NAALADase 
(N-acetylated-α-linked acidic dipeptidase, also called glutamate carboxypeptidase II, 
GCPII), an enzyme that hydrolyzes N-acetylaspartate-glutamate (NAAG) to N-
acetylaspartate (NAA) and glutamate (Neal et al., 2000, 2011). NAAG is an endogenous 
mGluR3 agonist, which negatively modulates the release of glutamate and other 
neurotransmitters (Neale et al., 2000, 2011). Given the important role of NAc glutamate in 
relapse to drug seeking as stated above, it was hypothesized that inhibition of NAALADase 
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by 2-PMPA and GPI-5693 would increase extracellular NAAG and decrease extracellular 
glutamate levels (due to decreased glutamate release from NAAG degradation), while the 
increase in NAAG would further inhibit glutamate release from neuronal terminals and/or 
glial cells by activating mGluR3 receptors (Xi et al., 2002a, 2010b). In addition, NAAG also 
inhibits DA release by activating mGluR3 receptors located on DA terminals in the NAc (Xi 
et al., 2010b). Thus, the endogenous NAALADase-NAAG-mGluR3 signal system may 
constitute a novel important target in medication development for the treatment of cocaine 
addiction. Earlier studies have shown that systemic administration of 2-PMPA inhibits 
cocaine-induced CPP (Slusher et al., 2001) and cocaine-induced behavioural sensitization 
(Shippenberg et al., 2000). Recently, we reported that systemic administration of 2-PMPA or 
GPI-5693 inhibited cocaine self-administration, cocaine-enhanced brain-stimulation reward, 
and cocaine-triggered reinstatement of drug-seeking behaviour (Xi et al., 2010a, 2010b; Peng 
et al., 2010b). This action was blocked by pretreatment with LY341495, a selective mGluR2/3 
antagonist. In addition, 2-PMPA dose-dependently attenuated cocaine-induced increases in 
extracellular DA and glutamate in the NAc (Xi et al., 2010a; 2010b). Taken together, these 
data suggest that inhibition of NAALADase by 2-PMPA or GPI-5693 produces an inhibitory 
effect on cocaine-taking and cocaine-seeking behaviour  
Clinical trials: GPI-5693 was investigated in a Phase I clinical trial for its safety, 
pharmacokinetics and efficacy for treatment of neuropathic pain (Table 3) (van der Post et 
al., 2005). It was reported to be safe and tolerable in healthy subjects.  
4.8 AMN082 
AMN082 is a novel systemically active mGluR7 PAM or agonist (Mitsukawa et al., 2005). 
The mGluR7 receptor subtype has attracted much attention in medication development for 
treatment of addiction for several reasons (Li et al., 2012). First, mGluR7 is the most 
abundant subtype of the group III mGluR subtypes in reward-related brain regions such as 
striatum, hippocampus and olfactory tubercles (Ferraguti and Shigemoto, 2006). Second, 
activation of group III mGluRs (including mGluR7) by L-AP4 inhibits DA and glutamate 
release in the NAc (Hu et al., 1999; Xi et al., 2003b). Third, it is the most conserved mGluR 
subtype across different mammalian species (Makoff et al., 1996), suggesting that selective 
mGluR7 ligands that are effective in experimental animals are more likely to be effective in 
humans. And fourth, the development of AMN082 has allowed us to explore the role of 
mGluR7 in drug reward and addiction.  
Based on the above, we and others have recently reported that systemic administration of 
AMN082 inhibits cocaine self-administration behaviour under both FR2 and PR 
reinforcement, cocaine-enhanced brain reward function, and cocaine-induced reinstatement 
of drug-seeking behaviour. In addition, AMN082 also decreases, while the selective mGluR7 
antagonist MMPIP increases, alcohol intake and preference (Salling et al., 2008; Bahi et al., 
2011). Importantly, the same doses of AMN082 neither alters locomotion or sucrose self-
administration (Li et al., 2010; Bahi et al., 2011; but see Salling et al., 2008) nor alters brain 
reward function (Li et al., 2008), suggesting that AMN082 produces therapeutic anti-cocaine 
effects without significant unwanted effects such as sedation, dysphoria or natural reward 
depression. Further mechanistic studies suggest that a NAc-VP GABAergic mechanism 
underlies its antagonism of cocaine reward (Li et al., 2008, 2009), while a glutamate-
mGluR2/3 mechanism underlies its antagonism of relapse to drug-seeking behaviour (Li et 
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al., 2008, 2010, 2012). Together, these preclinical data suggest a potential utility of AMN082 
in the treatment of cocaine addiction. AMN082 has not yet been tested in clinical trials. 
5. GABA-based medication strategies 
Rationale:  It is well known that the mesolimbic DA system is critically involved in drug 
reward and addiction. However, it remains unclear how increased NAc DA underlies these 
actions. Anatomically, the majority of neurons in the striatum are medium-spiny 
GABAergic output neurons, which receive DA projections from the VTA and glutamatergic 
projections predominantly from the prefrontal cortex, and project to the dorsal globus 
pallidus (from the dorsal striatum) and the ventral pallidum (VP) and VTA (from the ventral 
striatum, i.e. the NAc) (Bennett and Bolam, 1994; Groenewegen et al., 1996). Overall, DA 
produces a net inhibitory effect on striatal medium-spiny GABAergic neurons (Nicola and 
Malenka, 1997; Umemiya and Raymond, 1997), predominantly by activation of D2-like DA 
receptors (Centonze et al., 2002). Similarly, cocaine also produces an overall inhibitory effect 
on VTA GABAergic neurons (Cameron and Williams, 1994), striatal GABAergic neurons 
(Uchimura and North, 1990; White et al., 1993; Centonze et al., 2002; Schramm-Sapyta et al., 
2006), and GABA release in the VP (Tang et al., 2005; Li et al., 2010). Based on this, the NAc-
VP/VTA GABAergic projection constitutes common final pathway underlying drug reward 
and addiction (Figure 2). Thus, it has been hypothesized that a pharmacological strategy 
that enhances GABAergic transmission in the VTA and/or the VP would produce an 
inhibitory effect on cocaine- or DA-induced reductions in GABA release, therefore 
antagonizing cocaine’s rewarding effects. Based on this, several GABAergic compounds 
have been studied extensively in experimental animals.  
5.1 Gamma-vinyl GABA  
Preclinical studies: Gamma-vinyl GABA (GVG) (also called vigabatrin) is an irreversible 
GABA transaminase inhibitor.  GABA transaminase is an enzyme that breaks down GABA, 
causing an increase in brain GABA after GVG administration (Peng et al., 2010a). In the 
1990s, Dewey and colleagues first proposed that GVG might be useful for the treatment of 
drug addiction (Dewey et al., 1998). Since then, many preclinical studies appear to support 
this hypothesis (Xi and Gardner, 2008). Systemic administration of GVG inhibits cocaine 
self-administration, cocaine-enhanced brain-stimulation reward, cocaine-induced CPP and 
behavioural sensitization (see review by Xi and Gardner, 2008). Similarly, it also dose-
dependently inhibits cocaine-induced reinstatement of drug-seeking behaviour (Peng et al., 
2008). All these data support the use of GVG in the treatment of cocaine addiction.  
Clinical trials: GVG is currently under clinical trials for treatment of cocaine addiction (Table 
4). In three open-labeled studies, GVG was well-tolerated and produced a significant 
increase in cocaine abstinence rate (Brodie et al., 2003, 2005; Fechtner et al., 2006). In a more 
recent randomized, double-blind, placeto-controled trial, short-term GVG treatment 
significantly increased abstinence rate compared to placebo (Brodie et al., 2009). However, 
in another clinical trial for the treatment of methamphetamine dependence, GVG was not 
effective (De La Garza et al., 2009). GVG is not marketed in the USA because of concerns 
over ophthalmological side-effects, but none were observed during these short-term studies 
(Fechtner et al., 2006). More studies are underway to confirm its efficacy for cocaine 
dependence (http://clinicaltrials.gov).  
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Compound Company Pharm. Action Indication Status Reference 
GVG Aventis, 
Quebec, 
Canada 
GABA 
transaminase 
inhibitor 
Substance abuse
(cocaine, 
methamphetamine)
Phase II
 
 
http://clinicaltrials
.gov 
Topiramate Meliapharm, 
Montreal, 
Canada 
 
VIVUS, CA, 
USA 
GABAA PAM Substance abuse 
(cocaine) 
Phase II http://clinicaltrials
.gov 
Tiagabine Cephalon, PA, 
USA 
GABA 
transporter 
inhibitor 
Substance abuse
(cocaine); 
 
Anxiety 
Schizophrenia 
Phase II
 
 
Phase III 
http://clinicaltrials
.gov 
Baclofen Remedy 
Repack, 
PA, USA 
GABAB
receptor 
agonist 
Substance abuse
(cocaine, nicotine, 
alcohol) 
Phase II http://clinicaltrials
.gov 
Gabapentin Meliapharm, 
Montreal, 
Canada 
GABA 
enhancer, 
 
Alpha2delta-
Ca++ channel 
blocker 
Substance abuse
(cocaine, nicotine, 
alcohol) 
Phase II http://clinicaltrials
.gov 
Table 4. GABA receptor-based drug candidates in clinical trials 
5.2 Tiagabine 
Preclinical studies: Tiagabine is a selective type 1 GABA transporter (GAT1) inhibitor, which 
increases extracellular GABA levels (Eriksson et al., 1999). It has been approved as an 
antiepileptic medication (Schousboe et al., 2011). Preclinical studies suggest that tiagabine 
inhibited intravenous cocaine self-administration in rats (Filip et al., 2007) or baboons 
(Weerts et al., 2005), but had no significant effect on cocaine-induced reinstatement of drug-
seeking behaviour (Filip et al., 2007; Weerts et al., 2007). Our experimental data suggest that 
tiagabine, at much higher doses (10-20 mg/kg) than those used in the above-cited studies, 
selectively inhibited cocaine self-administration, but had no effect on cocaine-induced 
reinstatement of drug-seeking behaviour in rats (Yang et al., 2012). 
Clinical trials: The results of clinical trials with tiagabine are mixed. Two small-scale (45 and 
76 subjects, respectively) placebo-controlled clinical trials indicated that tiagabine produced 
a moderate reduction (~30%) in cocaine use in methadone-treated cocaine addicts (González 
et al., 2003, 2007), while other studies demonstrated that the same doses of tiagabine neither 
altered the acute effects of cocaine (Lile et al., 2004), nor lowered cocaine use in cocaine 
addicts (Winhusen et al., 2005; 2007).  
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5.3 Topiramate 
Preclinical studies: Topiramate is a positive modulator of GABAA receptors (acting at non-
benzodiazepine sites) and a licensed antiepileptic drug (Czuczwar and Patsalos, 2001). In 
addition, topiramate has other pharmacological actions, including antagonism of 
AMPA/kainate glutamate receptors, inhibition of voltage-gated sodium and calcium 
channels and inhibition of carbonic anhydrase (Johnson, 2005). In animal studies, topiramate 
was reported to inhibit cocaine self-administration and attenuate NAc DA response to 
cocaine or cocaine-associated cues (Johnson, 2005). 
Clinical studies: In a double-blind, placebo-controlled clinical trial (40 subjects), topiramate 
significantly increased abstinence rates compared to placebo (Kampman et al., 2004). A 
recent 12-week, open-label pilot study showed a significant reduction in craving intensity 
and duration in 25% of the sample group (Reis et al., 2008). Evidence for a beneficial role of 
topiramate in the treatment of cocaine dependence is promising but is limited by small 
sample sizes (Cubells, 2006; Minozzi et al., 2008). More studies are currently underway 
(Table 4). 
5.4 Baclofen 
Preclinical studies: Baclofen is a selective GABAB receptor agonist, licensed as an 
antispasmodic for patients with spinal cord injuries or multiple sclerosis. In rodents, 
pretreatment with baclofen dose-dependently attenuates cocaine self-administration under 
FR and PR reinforcement (Roberts et al., 1996; Brebner et al., 2000), cocaine-enhanced brain-
stimulation reward (Slattery et al., 2005), and cocaine-induced increases in NAc DA (Fadda 
et al., 2003). It also inhibited cocaine- or cue-induced cocaine-taking and cocaine-seeking 
behaviour (Di Ciano and Everitt, 2003; Campbell et al., 1999; Weerts et al., 2007).  
Clinical trials: In an initial open-label clinical trial, baclofen reduced self-reports of craving 
and cocaine use in 10 cocaine abusers (Ling et al., 1998). In a subsequent 16-week double-
blind study in 35 cocaine-dependent subjects, baclofen reduced cocaine use and increased 
the number of cocaine-free urines (Shoptaw et al., 2003), but did not alter cocaine craving. In 
a recent placebo-controlled, double-blind study, baclofen lowered cocaine intake, decreased 
cocaine craving, and attenuated cocaine’s cardiovascular effects in both cocaine- and opioid-
dependent subjects (Haney et al., 2006). However, a more recent large scale (160 cocaine 
addicts), double-blind, placebo-controlled clinical trial demonstrated that baclofen was not 
effective in attenuating cocaine use (Kahn et al., 2009). Thus, more studies are required to 
determine its efficacy in relapse prevention. 
5.5 Gabapentin 
Preclinical studies: Gabapentin is structurally analogous to GABA but, unlike the latter, it 
crosses the blood–brain barrier and can be administered systemically. Pharmacologically, 
gabapentin is a GABAmimetic drug that increases extracellular GABA levels, possibly by 
increasing the synthesis and nonvesicular release of GABA as well as by preventing GABA 
catabolism (Taylor et al., 1998). In addition, gabapentin also inhibits alpha2delta subunit-
composed voltage-dependent Ca++ channels (Gee et al., 1996). Early studies suggest that 
gabapentin (1-30 mg/kg, i.p.) significantly inhibited cocaine-induced hyperactivity and 
locomotor sensitization (Filip et al., 2006; but see Itzhak and Martin, 2000). However, other 
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studies demonstrate that gabapentin, at a broad dose range (10-200 mg/kg i.p.), neither 
inhibited cocaine self-administration nor altered cocaine-induced reinstatement of drug-
seeking behaviour in rats (Filip et al., 2007; Peng et al., 2008b). In vivo microdialysis studies 
demonstrate that gabapentin, at 100-200 mg/kg, produced a significant increase (~50 %) in 
extracellular GABA in the NAc, but failed to alter either basal or cocaine-enhanced NAc DA 
(Peng et al., 2008b). These data suggest that gabapentin is a weak GABA enhancer and may 
have limited potential in the treatment of cocaine addiction. 
Clinical trials: Early clinical studies and small-scale, open-label outpatient trials 
demonstrated that gabapentin reduced cocaine craving and use (Raby and Coomaraswamy, 
2004; Myrick et al., 2001; Hart et al., 2004, 2005). However, this finding was not repeated by 
larger-scale, double-blind, placebo-controlled clinical trials demonstrating that gabapentin, 
at doses up to 2400-3200 mg/day for 6-12 weeks, had no effect on abstinence rate, craving or 
subjective effects of cocaine (Bisaga et al., 2006; Berger et al., 2005; González et al., 2007; Hart 
et al., 2007). More clinical trials are currently under way to evaluate the effects of gabapentin 
or gabapentin combined with the antidepressant sertraline on cocaine or other addictive 
drug dependence (Table 4). 
6. Cannabinoid-based medication strategies 
Rationale: Marijuana is the most widely used illicit drug in the United States. ∆9-
tetrahydrocannabinol (∆9-THC) is the major psychoactive ingredient in marijuana. Two 
major types of cannabinoid receptors, CB1 and CB2, have been cloned. Since CB1 receptors 
are found in both brain and peripheral tissues, whereas CB2 receptors are found 
predominantly in peripheral immune system, it is generally belived that the psychoactive 
effects of ∆9-THC or marijuana are mediated by activation of brain CB1, not CB2, receptors 
(Tanda and Goldberg, 2003). However, growing evidence suggests that functional CB2 
receptors are also found in the brain (Van Sickle et al., 2005; Gong et al., 2006; Xi et al., 2011), 
suggesting that brain CB2 receptors may be also involved in marijuana’s actions. 
As stated above, the mesolimbic DA and the downstream NAc-VP GABAergic transmission 
have been thought to underlie cocaine reward and addiction. Growing evidence suggests 
that similar mechanisms may also underlie the action produced by ∆9-THC or marijuana. It 
was reported that ∆9-THC elevates extracellular DA in the NAc (Chen et al., 1990; Tanda et 
al., 1997). This action could be mediated by a GABAergic mechanism, i.e., ∆9-THC may 
initially activate CB1 receptors located on VTA GABAergic interneurons and produce a 
decrease in GABA release, which subsequently disinhibits (or activates) VTA DA neurons 
(Figure 2) (Fernandez-Ruiz et al., 2010). In addition, CB1 receptors are also highly expressed 
on presynaptic glutamatergic terminals in the NAc (Lupica et al., 2004). Thus, activation of 
CB1 receptors located on glutamatergic terminals decreases glutamate inputs onto medium-
spiny GABAergic neurons in the NAc and decrease GABA release in their projection areas – 
the VP and VTA. Further, CB1 receptors are also expressed on striatal GABAergic neurons, 
and activation of the CB1 receptors produces a direct inhibitory effect on medium-spiny 
GABAergic neurons and decreases GABA release in the VP and the VTA (Maldonado et al., 
2011). Lastly, cocaine or DA has been shown to increase endocannabinoid release in the 
striatum (Giuffrida et al., 1999; Centonze et al., 2004; Caille et al., 2007), which subsequently 
increases endocannabinoid binding to CB1 receptors located on presynaptic glutamatergic 
terminals and postsynaptic GABAergic neurons (Figure 2). Taken together, activation of 
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CB1 receptors located on both GABAergic and glutamatergic neurons causes an increase in 
NAc DA and a decrease in GABA release in both the VTA and VP. This decrease in NAc-VP 
GABAergic transmission constitutes a final common pathway underlying drug reward and 
addiction. Accordingly, blockade of CB1 receptors in both the VTA and NAc would 
attenuate the actions of cocaine on NAc DA and VP GABA release, and therefore attenuate 
cocaine reward and addiction. 
6.1 SR141716A  
Preclinical studies: SR141716A (also called rimonabant) is the first developed CB1 receptor 
antagonist (also an inverse agonist) (Rinaldi-Carmona et al., 1994). SR141716A was reported 
to inhibit cocaine self-administration under PR reinforcement (Soria et al., 2005; Xi et al., 
2008), decrease cocaine-enhanced NAc DA (Cheer et al., 2007; Soria et al., 2005), and inhibit 
cocaine- and cue-induced reinstatement of drug-seeking behaviour (De Vries et al., 2001), 
while other studies suggest that it has no effect on cocaine self-administration under low FR 
reinforcement, cocaine-induced CPP, or cocaine-induced behavioural sensitization (Arnold, 
2005). These data suggest that SR141716A may have therapeutic effects in attenuating 
relapse to drug-seeking behaviour, but is limited in terms of attenuating cocaine’s acute 
rewarding effects (Beardsley and Thomas, 2005; Xi and Gardner, 2008).   
Clinical trials:  SR141716A was the first CB1 receptor antagonist to be approved for clinical 
trials for the treatment of obesity and cigarette smoking. However, there are some safety 
concerns with rimonabant – increased risk of anxiety, depression, and suicide tendency, 
which had led it to being withdrawn from the market in Europe and North America in 2008. 
Since then, many pharmaceutical companies (Sanofi-Aventis, Merck, Pfizer, Solvay) have 
announced that they will stop further clinical research on this class of drug.  
6.2 AM251 
Preclinical studies: AM251 is a more potent and selective CB1 receptor antagonist than 
SR141716A (Krishnamurthy et al., 2004). In animal models of drug addiction, AM251 
appears to be more potent and effective than SR141716A in attenuating cocaine’s action (Xi 
et al., 2006, 2008). For example, AM251 significantly and dose-dependently inhibited cocaine 
self-administration (under PR, but not FR reinforcement) (Xi et al., 2008), cocaine-enhanced 
brain-stimulation reward (Xi et al., 2008), and cocaine-induced behavioural sensitization 
(Corbille et al., 2007), as well as cocaine-triggered reinstatement of drug-seeking behaviour 
(Xi et al., 2006). Further, a glutamate-mGluR2/3 mechanism has been shown to underlie the 
antagonism of reinstatement of drug seeking (Xi et al., 2006). That is, blockade of CB1 
receptors by AM251 elevates extracellular glutamate in the NAc, which subsequently 
increased glutamate binding to presynaptic mGluR2/3 receptors, inhibiting cocaine-induced 
increases in glutamate release and relapse to drug-seeking behaviour (Xi et al., 2006) (Figure 
3). These findings suggest that AM251 may be more potent and effective than SR141716A for 
treatment of cocaine addiction.  
Clinical trials: Since the above mentioned side-effects of SR141716A have been linked to its 
inverse agonist property, it is generally believed that AM251, a CB1 receptor antagonist with 
similar inverse agonist property might have the same unwanted side-effects. It is not under 
clinical trials.  
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6.3 JWH133 
Preclinical studies: In addition to CB1 receptors, recent breakthrough findings suggest that brain 
CB2 receptors are also involved in drug reward and addiction (Onaivi et al., 2008; Xi et al., 
2011; Aracil-Fernández, et al., 2012). JWH133 and GW405833 are highly selective CB2 receptor 
agonists. We have recently reported that systemic, intranasal or intra-NAc administration of 
JWH133 or GW405833 significantly and dose-dependently inhibits cocaine self-administration, 
cocaine-induced increases in locomotion and extracellular DA in wild-type and CB1-KO mice, 
but not in CB2-KO mice. Similarly, overexpression of CB2 receptors in mouse brain decreases 
intravenous cocaine self-administration and cocaine-induced locomotor sensitization (Aracil-
Fernández, et al., 2012). These data suggest that CB2 receptor agonists may have therapeutic 
potential for the treatment of cocaine addiction (Figure 2) (Xi et al., 2011).   
Clinical trials: JWH133 and GW405833 are currently not under clinical trials. However, many 
other selective CB2 receptor agonists, such as cannabinor, GW842166, GRC-10693, LY-
2828360, ABT-521, and KHK-6188, are currently under Phase I and Phase II clinical trials 
for the treatment of pain or other diseases (Table 5). In addition, several dual CB1/CB2  
 
Compound Company Pharm. Action Indication Status Reference 
Cannabinor Pharmos, 
NJ, USA 
CB2 agonist Pain Phase II
 
http://www.pharmoscorp
.com/development/canna
binor.html
GW842166 GSK, 
London, UK
CB2 agonist Pain Phase II http://clinicaltrials.gov 
GRC 10693 Glenmark,
Munbai, 
India
CB2 agonist Pain Phase I http://www.evaluatephar
ma.com/Universal/View.a
spx?type=Story&id=183092 
LY-2828360 Eli Lilly, 
USA
CB2 agonist Pain Phase II http://clinicaltrials.gov 
ABT-521 Abbott, USA CB2 agonist Pain Phase I http://www.pharmalive.c
om/special_reports/sampl
e.cfm?reportID=283 
KHK-6188 Kyowa 
Hakka Kirin, 
Japan
CB2 agonist Pain Phase I http://clinicaltrials.gov 
Nabilone 
(Cesamet): 
∆9-THC 
analog 
NEMA 
Research, 
USA 
CB1/CB2 
agonist 
Cannabis 
addiction; 
 
Pain 
Phase III
 
 
Phase IV 
http://clinicaltrials.gov 
Marinol 
(Dronabinol): 
∆9-THC 
UNIMED, 
USA 
CB1/CB2 
agonist 
Substance
abuse 
(opioid, 
marijuana, 
alcohol), 
PTSD
Phase II
 
 
 
 
Phase IV
http://clinicaltrials.gov 
Sativex:  
∆9-THC + 
Cannabidiol 
GW, 
London, UK
CB1/CB2 
agonist 
Cannabis 
abuse, 
Pain 
Phase II http://clinicaltrials.gov 
Table 5. Cannabinoid-based drug candidates in clinical trials 
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receptor agonists such as Nabilone (a ∆9-THC analog), Marinol (∆9-THC), Sativex (a mixture 
of THC and cannabidiol) have been approved for the treatment of pain and chemotherapy-
induced nausea and vomiting (Table 5). Based upon the recent findings that activation of 
CB2 receptors in primary afferents and spinal cord produces analgesic effects (Anand et al., 
2009; Beltramo, 2009), and that activation of CB2 receptors in the brainstem inhibits 
morphine-6-glucuronide–induced emesis (vomiting) (Van Sickle et al., 2005), it is likely that 
the therapeutic effects of these dual CB1/CB2 receptor agonists may at least in part be 
mediated by activation of brain CB2 receptors.   
7. Conclusion  
In this review article, I first briefly reviewed the neurochemical mechanisms underlying 
cocaine reward and addiction, and then provided the rationale for development of various 
pharmacological therapies for the treatment of cocaine addiction. Lastly, I summarized the 
major findings of multiple pharmacological agents in each drug catagory in animal models 
of drug addiction and the current status in clinical trials for the treatment of drug addiction 
and/or other neuropsychiatric diseases. In summary, the VTA-NAc-VP pathway, including 
the mesolimbic DA and the NAc-VP GABAergic transimission, appears to play a critical role 
in mediating cocaine’s rewarding effects (Figure 2), while a NAc glutamate-mGluR2/3 
mechanism plays an important role in controlling relapse to drug-seeking behaviour (Figure 
3). Accordingly, various pharmacological agents have been proposed and tested in animal 
models of drug addiction to interfere with the pharmacological actions produced by cocaine. 
Among those compounds discussed above, the DAT inhibitors (modafinil, RTI-335, 
CTDP31,345, CTDP-32,476), the DA receptor antagonists (l-THP, S33138, GSK598809, YQA-
14) and the glutamatergic ligands (NAC, MPEP, LY369268, 2-PMPA) appear to be promising 
in preclinical animal models of drug addiction. In addition, several compounds (such as 
modafinil, disulfram, topiramate) were initially found to be effective in humans with 
unknown mechanisms, while subsequent preclinical studies helped to uncover the 
mechanisms of the actions. Although many compounds are currently or at some point were, 
under clinical trials, most of them have been used to evaluate their safety and efficacy for 
other neuropsychiatric diseases such schizophrenia, anxiety, obesity or smoking, rather than 
for cocaine addiction. Clearly, more translational studies from preclinical research to human 
clinical trials are required to promote the medication discovery for the treatment of cocaine 
dependence.  
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